REDEFINE 1Essai clinique du CagriSema pour la perte de poids chez les participants souffrant de surpoids ou d'obésité

Cagrilintide

Placebo semaglutide

Cagrilintide

Semaglutide

Semaglutide

Placebo cagrilintide

Placebo cagrilintide

Placebo semaglutide

CagriSema versus placebo: Relative change in body weight

CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction

CagriSema versus placebo: Change in waist circumference

CagriSema versus placebo: Relative change in body weight

CagriSema versus placebo: Achievement of >= 20% weight reduction

CagriSema versus placebo: Achievement of >= 25% weight reduction

CagriSema versus placebo: Achievement of >= 30% weight reduction

CagriSema versus cagrilintide and CagriSema versus semaglutide: Relative change in body weight

CagriSema versus placebo: Relative change in body weight

CagriSema versus placebo: Change in systolic blood pressure (SBP)

CagriSema versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score

CagriSema versus placebo: Change in SF-v2 Health Survey Acute (SF-36 v2 Acute) Physical Functioning Score

CagriSema versus placebo, semaglutide and cagrilintide: Change in body weight

CagriSema versus placebo, semalutide and cagrilintide: Change in body mass index (BMI)

CagriSema versus placebo, semaglutide and cagrilintide: Improvement in weight category

CagriSema versus placebo: Change in Glycated Haemoglobin (HbA1c)

CagriSema versus placebo: Change in HbA1c

CagriSema versus placebo: Change in Fasting Plasma Glucose (FPG) (mmol/L).

CagriSema versus placebo: Change in FPG (mg/dL)

CagriSema versus placebo: Ratio to baseline in fasting serum insulin

CagriSema versus placebo: Change in Diastolic Blood Pressure (DBP)

CagriSema versus placebo: Ratio to baseline in total cholesterol

CagriSema versus placebo: Ratio to baseline in High-density lipoprotein (HDL) cholesterol

CagriSema versus placebo: Ratio to baseline in Low-density lipoprotein (LDL) cholesterol

CagriSema versus placebo: Ratio to baseline in Very low-density lipoprotein (VLDL) cholesterol

CagriSema versus placebo: Ratio to baseline in Triglycerides

CagriSema versus placebo: Ratio to baseline in Free fatty acids

CagriSema versus semaglutide and cagrilintide: Change in waist circumference

CagriSema versus semaglutide and cagrilintide: Change in SBP

CagriSema versus semaglutide and cagrilintide: Ratio to baseline in total cholesterol

CagriSema versus semaglutide and cagrilintide: Ratio to baseline in HDL

CagriSema versus semaglutide and cagrilintide: Ratio to baseline in LDL

CagriSema versus semaglutide and cagrilintide: Ratio to baseline in VLDL

CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Triglycerides

CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Free fatty acids

CagriSema versus placebo: Relative change in body weight (Measured in kilograms (kg))

CagriSema versus placebo: Relative change in body weight (Measured in percentage (%))

CagriSema versus placebo: Absolute change in body weight (Measured in kilograms (kg))

CagriSema versus placebo: Absolute change in body weight (Measured in percentage (%))

CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as kilograms (kg))

CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as percentage (%))

CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as kilograms (kg))

CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as percentage (%))

CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as percentage (%))

CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as %-points)

CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as percentage (%))

CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as %-points)

CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in kilograms (kg))

CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in percentage (%))

CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in kilograms (kg))

CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in percentage (%))

CagriSema versus placebo: Achievement of at least 14.6- point increase (yes/no) in IWQOL-Lite-CT Physical Function score

CagriSema versus placebo: Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Physical Functioning score

CagriSema versus placebo: Change in IWQOL-Lite-CT - Physical Function Score

CagriSema versus placebo: Change in IWQOL-Lite-CT - Psychosocial Score

CagriSema versus placebo: Change in IWQOL-Lite-CT - Total Score

Change in Control of Eating (COEQ): Craving Control Score

Change in COEQ: Craving for Savoury food score

Change in COEQ: Hunger score

Change in COEQ: Craving for Sweets Score

Change in COEQ: Positive Mood score

Change in COEQ: Satiety score

CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Change in IWQOL-Lite-CT Physical Function score

CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score

CagriSema versus placebo, semalutide and cagrilintide: Ratio to baseline C-reactive protein (CRP)

Number of Treatment Emergent Adverse Events (TEAEs)

Number of Treatment Emergent Serious adverse events (TESAEs)